Patent intelligence · US
US 11964047
Ophthalmic formulations and related methods
Ophthalmic formulations and related methods
Patent details — US 11964047
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 23, 2024
- Expiration
- Apr 18, 2044
- Applicant
- ETERNATEAR, INC.
- Claims
- 18
- CPC classes
- A61K, A61K47/24, A61K47/26, A61K47/44
Quick answer
US 11964047 (Ophthalmic formulations and related methods) is held by ETERNATEAR, INC.. Status: granted. Granted Apr 23, 2024. Expires Apr 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ETERNATEAR, INC.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K47/24, A61K47/26, A61K47/44, A61K9/0048, A61K9/1075
More from ETERNATEAR, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12226429
Highly active compounds against COVID-19
granted -
US 12084473
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 12006340
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
granted -
US 12005139
Ophthalmic formulations and related methods
granted -
US 11975016
2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
granted -
US 11833160
Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases
granted -
US 11813278
Highly active compounds against COVID-19
granted
Frequently asked questions
What is US patent 11964047?
US 11964047 (Ophthalmic formulations and related methods) is held by ETERNATEAR, INC.. Status: granted. Granted Apr 23, 2024. Expires Apr 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11964047?
ETERNATEAR, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 11964047 expire?
Our index shows an expiration date of Apr 18, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.